3.2 Grading
Grading is a critical element in treatment planning and should be clearly documented in the patient’s medical record. High-grade gliomas are classified as high-grade tumours.
Grading for high-grade gliomas involves both:
- neuroimaging with MRI +/– CT
- histological testing.
Genetic testing of the tumour should be conducted where relevant to determine appropriate treatment options. The following genetic tests may benefit patients with high-grade gliomas:
- IDH1/IDH2 mutation
- 1p/19q codeletion
- MGMT methylation
- TERT promoter methylation (EMSO 2017)
- EGFR amplification or mutation
- ATRX mutation.
Visit the Cancer Institute New South Wales website for information about understanding the stages of cancer.